REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors
Nov 29, 2016 13:01 pm UTC| Business
ROCKVILLE, Md. and CAMBRIDGE, Mass., Nov. 29, 2016 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV)...
Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium
Nov 29, 2016 13:01 pm UTC| Business
DURHAM, N.C., Nov. 29, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium
Nov 29, 2016 13:01 pm UTC| Business
DURHAM, N.C., Nov. 29, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Nov 29, 2016 13:00 pm UTC| Business
CAMBRIDGE, Mass., Nov. 29, 2016 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human...
Voyager Therapeutics and REGENXBIO Announce Exercise of Options for Rights to NAV Vectors
Nov 29, 2016 13:00 pm UTC| Business
CAMBRIDGE, Mass., and ROCKVILLE, Md., Nov. 29, 2016 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous...
Newest Bullion Coin Launches To Much Fanfare
Nov 29, 2016 13:00 pm UTC| Business
LUTZ, Fla., Nov. 29, 2016 -- Gainesville Coins LLC, one of the nation's largest precious metal dealers, is introducing an exclusive new product, the 2017 1 oz Guardian Angel Silver Coin. Struck as legal tender coins for...
Bioblast Pharma Reports Third Quarter 2016 Financial Results
Nov 29, 2016 13:00 pm UTC| Business
TEL AVIV, Israel, Nov. 29, 2016 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September 30, 2016. ...